Published in Health Risk Factor Week, July 19th, 2005
"Irinotecan combined with continuous-infusion 5FU has been shown to be an effective and tolerable regimen in the treatment of MCRC. UFT during 5FU infusion enhances plasma 5FU concentration, mimics continuous 5FU infusion and delivers the drug to target tumor cells," researchers in Japan reported.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Risk Factor Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.